LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting

Reuters

Oct 07

LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting

LivaNova plc has announced its upcoming participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis, where the company will present new scientific data on its aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). The company will deliver a five-year analysis from the THN-3 randomized controlled trial, as well as 12-month top-line data from the follow-on OSPREY randomized controlled trial. The results, which demonstrate the durability and retention of benefits of proximal hypoglossal nerve stimulation (p-HGNS) therapy, will be shared during oral and poster presentations scheduled for October 9 and 10, 2025. In November 2024, LivaNova announced that the OSPREY trial met its primary and secondary endpoints after six months of therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007619591) on October 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573396884"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573396884\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573396884?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573396884","market":"fut","top_or_hot":-1,"title":"LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        LivaNova plc has announced its upcoming participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis, where the company will present new scientific data on its aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). The company will deliver a five-year analysis from the THN-3 randomized controlled trial, as well as 12-month top-line data from the follow-on OSPREY randomized controlled trial. The results, which demonstrate the durability and retention of benefits of proximal hypoglossal nerve stimulation (p-HGNS) therapy, will be shared during oral and poster presentations scheduled for October 9 and 10, 2025. In November 2024, LivaNova announced that the OSPREY trial met its primary and secondary endpoints after six months of therapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007619591) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-07 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        LivaNova plc has announced its upcoming participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis, where the company will present new scientific data on its aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). The company will deliver a five-year analysis from the THN-3 randomized controlled trial, as well as 12-month top-line data from the follow-on OSPREY randomized controlled trial. The results, which demonstrate the durability and retention of benefits of proximal hypoglossal nerve stimulation (p-HGNS) therapy, will be shared during oral and poster presentations scheduled for October 9 and 10, 2025. In November 2024, LivaNova announced that the OSPREY trial met its primary and secondary endpoints after six months of therapy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007619591) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LIVN","symbol_name":"LivaNova PLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDLbLhhmg:1","article_id":"2573396884","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573396884","pubTimestamp":1759842056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"LivaNova Unveils Positive Five-Year Clinical Data for aura6000 System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire  on October 07, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LIVN":"LivaNova PLC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4082":"医疗保健设备","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC"},"translate_title":"LivaNova公布aura6000积极的五年临床数据™ISSS 2025年年会上治疗阻塞性睡眠呼吸暂停的系统","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIVN":0.9},"content_text":"LivaNova Unveils Positive Five-Year Clinical Data for aura6000™ System in Treating Obstructive Sleep Apnea at ISSS 2025 Annual Meeting\n    \n\n        LivaNova plc has announced its upcoming participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis, where the company will present new scientific data on its aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). The company will deliver a five-year analysis from the THN-3 randomized controlled trial, as well as 12-month top-line data from the follow-on OSPREY randomized controlled trial. The results, which demonstrate the durability and retention of benefits of proximal hypoglossal nerve stimulation (p-HGNS) therapy, will be shared during oral and poster presentations scheduled for October 9 and 10, 2025. In November 2024, LivaNova announced that the OSPREY trial met its primary and secondary endpoints after six months of therapy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007619591) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}